Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Short term Debt (2016 - 2017)

Bone Biologics (BBLG) has disclosed Short term Debt for 2 consecutive years, with $12.9 million as the latest value for Q3 2017.

  • On a quarterly basis, Short term Debt rose 43.33% to $12.9 million in Q3 2017 year-over-year; TTM through Sep 2017 was $12.9 million, a 43.33% increase, with the full-year FY2016 number at $1.2 million, changed N/A from a year prior.
  • Short term Debt was $12.9 million for Q3 2017 at Bone Biologics, up from $12.2 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $12.9 million in Q3 2017 to a low of $1.2 million in Q4 2016.